童颜针市场增长

Search documents
童颜针代理权仲裁进展:韩方公司暂禁自行销售,*ST苏吴继续供货
Guan Cha Zhe Wang· 2025-09-12 07:54
Core Viewpoint - The temporary injunction issued by the Shenzhen International Arbitration Court prevents Regen Biotech from selling AestheFill in mainland China and denies its claim to terminate the exclusive agency agreement with Datou Medical, safeguarding a distribution right valued at at least 1.6 billion yuan for *ST Suwu's subsidiary [1][6]. Group 1: Market Dynamics - The Chinese aesthetic medicine market, particularly the AestheFill market, is experiencing explosive growth, with the market size increasing from approximately 100 million yuan in 2021 to over 3.2 billion yuan by 2025, representing a compound annual growth rate (CAGR) of 54% [1][7]. - The rapid expansion of the AestheFill market has attracted numerous companies, highlighting the intense competition and significant profit potential within the aesthetic medicine sector [1][8]. Group 2: Legal Proceedings - The arbitration case originated from a March 2025 acquisition of 85% of Regen Biotech by Aimeike for $190 million, followed by Regen's termination of the exclusive distribution agreement with Datou Medical [4][6]. - Datou Medical filed for arbitration on August 7, 2025, seeking to confirm the validity of the exclusive agency agreement and claiming initial damages of 1.6 billion yuan, with the right to adjust the claim amount [6][8]. Group 3: Product Insights - AestheFill, a popular product in the aesthetic medicine field, contains poly-L-lactic acid (PLLA), which stimulates collagen production, offering a more natural and long-lasting effect compared to traditional fillers [7]. - The approval of compliant AestheFill products in China has increased, with the number rising from 5 in 2024 to 9 by July 2025, indicating a growing acceptance and market presence [7].